Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan W Friedberg

Showing results (201-210 of 300) with videos related to

Pageof 30
Sort By:
Clinical Lymphoma & Myeloma|September 1, 2009
Outcomes of patients with Burkitt lymphoma older than age 40 treated with intensive chemotherapeutic regimensJennifer L Kelly, Stephen R Toothaker, Lauren Ciminello, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 22, 2016
Late Relapses After High-dose Chemotherapy and Autologous Stem Cell Transplantation in Patients With Diffuse Large B-cell Lymphoma in the Rituximab EraBradley D Hunter, Megan Herr, Philip J Meacham, et al.
Journal of the National Cancer Institute. Monographs|September 1, 2014
Medical history, lifestyle, family history, and occupational risk factors for sporadic Burkitt lymphoma/leukemia: the Interlymph Non-Hodgkin Lymphoma Subtypes ProjectSam M Mbulaiteye, Lindsay M Morton, Joshua N Sampson, et al.
Oncotarget|July 6, 2015
Inhibition of COP9-signalosome (CSN) deneddylating activity and tumor growth of diffuse large B-cell lymphomas by doxycyclineMary Pulvino, Luojing Chen, David Oleksyn, et al.
Cancer|August 8, 2013
Stem cell transplantation for follicular lymphoma relapsed/refractory after prior rituximab: a comprehensive analysis from the NCCN lymphoma outcomes projectAndrew M Evens, Ann Vanderplas, Ann S LaCasce, et al.
Blood|November 26, 2014
Elevated serum levels of IL-2R, IL-1RA, and CXCL9 are associated with a poor prognosis in follicular lymphomaMuhammad A Mir, Matthew J Maurer, Steven C Ziesmer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 10, 2008
Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent studyJonathan W Friedberg, Philip Cohen, Ling Chen, et al.
Cancer|December 11, 2014
Radiation for diffuse large B-cell lymphoma in the rituximab era: analysis of the National Comprehensive Cancer Network lymphoma outcomes projectBouthaina S Dabaja, Ann M Vanderplas, Allison L Crosby-Thompson, et al.
Blood Cancer Journal|October 16, 2025
Advanced stage classical Hodgkin lymphoma patients with a positive interim-PET (PET-2) Deauville score 5 after 2 ABVD cycles: a pooled analysis of three multicenter trialsSimonetta Viviani, Chiara Pavoni, Sally F Barrington, et al.
Journal of the National Cancer Institute|December 18, 2016
General Biomarker Recommendations for LymphomaLisa Rimsza, Yuri Fedoriw, Louis M Staudt, et al.
Pageof 30

Showing results (201-210 of 300) with videos related to

Sort By:
Pageof 30
Clinical Lymphoma & Myeloma|September 1, 2009
Outcomes of patients with Burkitt lymphoma older than age 40 treated with intensive chemotherapeutic regimensJennifer L Kelly, Stephen R Toothaker, Lauren Ciminello, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 22, 2016
Late Relapses After High-dose Chemotherapy and Autologous Stem Cell Transplantation in Patients With Diffuse Large B-cell Lymphoma in the Rituximab EraBradley D Hunter, Megan Herr, Philip J Meacham, et al.
Journal of the National Cancer Institute. Monographs|September 1, 2014
Medical history, lifestyle, family history, and occupational risk factors for sporadic Burkitt lymphoma/leukemia: the Interlymph Non-Hodgkin Lymphoma Subtypes ProjectSam M Mbulaiteye, Lindsay M Morton, Joshua N Sampson, et al.
Oncotarget|July 6, 2015
Inhibition of COP9-signalosome (CSN) deneddylating activity and tumor growth of diffuse large B-cell lymphomas by doxycyclineMary Pulvino, Luojing Chen, David Oleksyn, et al.
Cancer|August 8, 2013
Stem cell transplantation for follicular lymphoma relapsed/refractory after prior rituximab: a comprehensive analysis from the NCCN lymphoma outcomes projectAndrew M Evens, Ann Vanderplas, Ann S LaCasce, et al.
Blood|November 26, 2014
Elevated serum levels of IL-2R, IL-1RA, and CXCL9 are associated with a poor prognosis in follicular lymphomaMuhammad A Mir, Matthew J Maurer, Steven C Ziesmer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 10, 2008
Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent studyJonathan W Friedberg, Philip Cohen, Ling Chen, et al.
Cancer|December 11, 2014
Radiation for diffuse large B-cell lymphoma in the rituximab era: analysis of the National Comprehensive Cancer Network lymphoma outcomes projectBouthaina S Dabaja, Ann M Vanderplas, Allison L Crosby-Thompson, et al.
Blood Cancer Journal|October 16, 2025
Advanced stage classical Hodgkin lymphoma patients with a positive interim-PET (PET-2) Deauville score 5 after 2 ABVD cycles: a pooled analysis of three multicenter trialsSimonetta Viviani, Chiara Pavoni, Sally F Barrington, et al.
Journal of the National Cancer Institute|December 18, 2016
General Biomarker Recommendations for LymphomaLisa Rimsza, Yuri Fedoriw, Louis M Staudt, et al.
Pageof 30